TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1091434
Drug: Tolbutamide Ratiopharm
Normalized name: Tolbutamide
DrugBank: Tolbutamide (DB01124)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tolbutamide Ratiopharm (1,000 mg)
Study: 31870306
Drug: Community Occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community Occupational Therapy in Dementia-UK intervention (COTiD-UK)
Study: 19446150
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (established tablet) of amlodipine besylate (10 mg)
Study: 14742377
Drug: Nefopam and
Normalized name: nefopam
DrugBank: Nefopam (DB12293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam and Morphine combination
Study: 14742377
Drug: Nefopam and
Normalized name: nefopam
DrugBank: Nefopam (DB12293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam and Morphine
Study: 9040200
Drug: OAM (omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAM (omeprazole 20 mg b.i.d., amoxicillin 750 mg b.i.d., metronidazole 400 mg b.i.d.)
Study: 9040200
Drug: OCM (omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCM (omeprazole 20 mg b.i.d., clarithromycin 250 mg b.i.d., metronidazole 400 mg b.i.d.)
Study: 9040200
Drug: BCM (bismuth
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCM (bismuth subcitrate 240 mg b.i.d., clarithromycin 250 mg b.i.d., metronidazole 400 mg b.i.d.)
Study: 3317347
Drug: Yeast-derived vaccine
Normalized name: YEAST CELL,LIVE DERIVATIVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yeast-derived vaccine (10, 20, or 40 micrograms)
Study: 3317347
Drug: Plasma-derived vaccine
Normalized name: Haptoglobulin 1/1 (Plasma Derived)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma-derived vaccine (5 micrograms, Institut Pasteur Production)
Study: 3317347
Drug: Plasma-derived vaccine
Normalized name: Haptoglobulin 1/1 (Plasma Derived)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma-derived vaccine (20 micrograms, Merck Sharp & Dohme)
Study: 30097463
Drug: SC411 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC411 at 20 mg DHA/kg per day
Study: 30097463
Drug: SC411 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC411 at 60 mg DHA/kg per day
Study: 30097463
Drug: Pooled active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pooled active groups (SC411 at 20, 36, and 60 mg DHA/kg per day)
Study: 30097463
Drug: SC411 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC411 (all doses)
Study: 18468289
Drug: Stimulant medication
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulant medication
Study: 26094763
Drug: Nurse titrated
Normalized name: PAD,NURSING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse titrated analgesia (treatment as usual)
Study: 19840018
Drug: Chemotherapy in
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy in patients with germ-cell cancer
Study: 10849389
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin (BTX) injection (bilateral)
Study: 8886735
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of morphine
Study: 3887076
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of lidocaine
Study: 29355439
Drug: Glucagon administration
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glucagon administration
Study: 28238161
Drug: Ligasure™ (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ligasure™ (Group L)
Study: 28238161
Drug: EBDs (especially
Approvals — FDA: no, EMA: no, PMDA: no
Description: EBDs (especially Group L)
Study: 18631332
Drug: All antiallergic
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All antiallergic agents
Study: 11134190
Drug: Clodronate 1,600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate 1,600 mg daily for 3 years
Study: 16317063
Drug: Lispro insulin
Normalized name: Lispro insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lispro insulin
Study: 2647105
Drug: Amoxicillin‐clavulanate potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin‐clavulanate potassium treatment
Study: 786672
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of acebutolol
Study: 28283902
Drug: Low-dose combined
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose combined (IV + IA injection of 1 g)
Study: 25580725
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with rifapentine and isoniazid (12 once-weekly doses for 3 months)
Study: 22024000
Drug: Buprenorphine/naloxone (Bup/Nal)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine/naloxone (Bup/Nal) therapy for 12 weeks
Study: 22024000
Drug: Buprenorphine/naloxone detoxification
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine/naloxone detoxification for up to 2 weeks with weekly individual and group drug counseling
Study: 22024000
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment opioid abstinence (weeks 1 and 2)
Study: 22024000
Drug: Additional nonstudy
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional nonstudy treatments during the study
Study: 19166684
Drug: Lovastatin (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (low or high doses)
Study: 27628763
Drug: Warfarin (low-dose)
Normalized name: ethinyl estradiol
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Warfarin (low-dose)
Study: 11126152
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg of intravenous fesin for 7 successive hemodialysis sessions
Study: 29091995
Drug: Switched treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switched treatment (alternating treatment with biosimilar and reference filgrastim)
Study: 11195876
Drug: Manual lymph
Normalized name: Bos taurus lymph preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual lymph drainage (10 treatments)
Study: 11195876
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (conventional treatment with exercises, movement, oedema control, and education)
Study: 17261397
Drug: Pravastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (40 mg/day)
Study: 29931843
Drug: Ligustrazine hydrochloride
Normalized name: ligustrazine
DrugBank: Ligustrazine (DB19074)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ligustrazine hydrochloride injection (LHI)
Study: 20339787
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (group C)
Study: 24807158
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus radiotherapy (CRT)
Study: 24807158
Drug: Chemotherapy (without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (without CRT)
Study: 19695854
Drug: Simvastatin/Fluvastatin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin/Fluvastatin treatment for 16 weeks
Study: 12600905
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (136 IU) plus slow-release vitamin C (250 mg) twice daily
Study: 30795753
Drug: Saffron (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saffron (100 mg/d)
Study: 22287037
Drug: FR-aspirin 650
Normalized name: aspirin 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: FR-aspirin 650 mg
Study: 22287037
Drug: FR-aspirin 1000
Normalized name: aspirin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: FR-aspirin 1000 mg
Study: 22287037
Drug: R-aspirin 650
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-aspirin 650 mg
Study: 22287037
Drug: R-aspirin 1000
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-aspirin 1000 mg
Study: 19865059
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of enoxaparin sodium and bed rest (Group B)
Study: 19865059
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of enoxaparin sodium and thigh-length compression stockings (Group C)
Study: 19865059
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of enoxaparin sodium and pneumatic compression (Group D)
Study: 19865059
Drug: Intravenous unfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous unfractionated heparin (Group A)
Study: 17526857
Drug: Emtricitabine in
Normalized name: Product containing emtricitabine in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emtricitabine in combination with stavudine
Study: 17526857
Drug: Emtricitabine in
Normalized name: Product containing emtricitabine in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emtricitabine in combination with famciclovir
Study: 17526857
Drug: Emtricitabine in
Normalized name: Product containing emtricitabine in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emtricitabine in combination with zidovudine
Study: 17526857
Drug: Emtricitabine in
Normalized name: Product containing emtricitabine in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emtricitabine in combination with zidovudine glucuronide
Study: 14504156
Drug: Intrathecal tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal tramadol 25 mg
Study: 14504156
Drug: Saline 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 0.5 ml
Study: 10476732
Drug: further chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: further chemotherapy cycles
Study: 28056917
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered subcutaneously at weeks 1, 5, and 9
Study: 28056917
Drug: Fulranumab 9
Normalized name: Fulranumab
DrugBank: Fulranumab (DB12102)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fulranumab 9 mg
Study: 25001267
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group received a 20 stipend monthly and engaged in social/leisure activities for 2 hours weekly over a 9-month period.
Study: 25001267
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received a 20 monthly stipend and engaged in a weekly social/leisure activity.
Study: 10692984
Drug: Raloxifene 60
Normalized name: raloxifene 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 60 mg/day and 150 mg/day
Study: 8741209
Drug: Berberine 200
Normalized name: Dihydroberberine 200 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Berberine 200 mg
Study: 8741209
Drug: Nicotinic acid
Normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotinic acid 2 g
Study: 8741209
Drug: Tetracycline (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline (single dose)
Study: 1914797
Drug: Soluble human
Normalized name: Recombinant soluble human CD4
DrugBank: Recombinant soluble human CD4 (DB17782)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble human insulin (Actrapid HM U-100)
Study: 7121133
Drug: Mexiletine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexiletine (200 mg three times per day)
Study: 31278907
Drug: Nasal cannula
Normalized name: EUCALYPTUS OIL 0.15 g in 1 g / MENTHOL, UNSPECIFIED FORM 0.2 g in 1 g / ARGININE 0.1 g in 1 g TOPICAL CREAM [Slimming Detox Nasal Cannula]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal cannula group (O2 [2 L/minute] via nasal cannula)
Study: 22515513
Drug: HD203 (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: HD203 (25 mg/mL, administered subcutaneously)
Study: 22515513
Drug: Enbrel® (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enbrel® (25 mg/mL, administered subcutaneously)
Study: 25961781
Drug: BMS-820836 flexible
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BMS-820836 flexible dose (0.5-2 mg/d)
Study: 25961781
Drug: BMS-820836 fixed
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BMS-820836 fixed dose (1 mg/d or greater)
Study: 25961781
Drug: BMS-820836 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-820836 (2 mg/d)
Study: 19298914
Drug: Heparin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin and glycoprotein IIb/IIIa inhibitors
Study: 3289675
Drug: terodiline 25
Normalized name: terodiline 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: terodiline 25 mg bd
Study: 3289675
Drug: emepronium bromide
Normalized name: emepronium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: emepronium bromide 200 mg tds
Study: 25710507
Drug: CXL treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CXL treatment (0.1% riboflavin drops and UV-A irradiation at 365 nm for 30 minutes)
Study: 23787458
Drug: CXL treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CXL treatment
Study: 21345638
Drug: Antibody persistence
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibody persistence evaluation
Study: 16441800
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of dexamethasone
Study: 10811673
Drug: Docetaxel 100
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 100 mg/m(2) given as a 1‐hour intravenous infusion every 3 weeks
Study: 1457907
Drug: Quinine 325
Normalized name: quinine 325 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine 325 mg at bedtime
Study: 28902105
Drug: Intra-articular Corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular Corticosteroid Injection (ICI)
Study: 1444724
Drug: Caffeine (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (both doses)
Study: 20613496
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of telmisartan (80 mg) and amlodipine (10 mg)
Study: 7843758
Drug: Amlodipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (10 mg)
Study: 20399994
Drug: Rosuvastatin 5
Normalized name: rosuvastatin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 5 mg
Study: 18042475
Drug: Rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 10 mg (fed state)
Study: 15122133
Drug: 0.2% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% ropivacaine PCA infusion at 5 mL per hour with a bolus dose of 2 mL at a 15-minute lockout period (group I)
Study: 15122133
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion under the same conditions (group II)
Study: 9619811
Drug: Willingness to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Willingness to participate in a randomized vaccine efficacy trial
Study: 9619811
Drug: Baseline knowledge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline knowledge of vaccine trial concepts
Study: 326495
Drug: Indapamide (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indapamide (2.5 mg to 5 mg)
Study: 28068596
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus omega 3
Study: 21204889
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with VCE supplementation (vitamin C 500 mg tablet and vitamin E 400 mg gelatin capsule)
Study: 21204889
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (5‐fluorouracil 500 mg/m(2) i.v. day 1, doxorubicin 50 mg/m(2) i.v. day 1, cyclophosphamide 500 mg/m(2) i.v. day 1, every 3 weeks for six cycles)
Study: 17445266
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg 5-ALA via inhalation 1, 2, 3, 4 or 6 hours before bronchoscopy
Study: 17445266
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg 5-ALA via inhalation
Study: 17445266
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg 5-ALA via inhalation 160 min prior to bronchoscopy
Study: 15610951
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose transdermal nicotine patch (14 or 21 mg)
Study: 2357862
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg caffeine plus 75 mg phenylpropanolamine
Study: 2357862
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg caffeine alone
Study: 2357862
Drug: phenylpropanolamine-caffeine combination
Normalized name: caffeine / phenylpropanolamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: phenylpropanolamine-caffeine combination
Study: 25589326
Drug: Albendazole plus
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole plus oxantel pamoate (400 mg + 20 mg/kg)
Study: 25589326
Drug: Albendazole plus
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole plus ivermectin (400 mg + 200 μg/kg)
Study: 25589326
Drug: Mebendazole alone
Normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mebendazole alone (500 mg)
Study: 25589326
Drug: Albendazole plus
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole plus mebendazole (400 mg + 500 mg)
Study: 22967344
Drug: Acarbose 50
Normalized name: acarbose 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose 50 mg added to insulin treatment
Study: 22967344
Drug: Preprandial ultra-short
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preprandial ultra-short effect insulin and long-acting insulin before bedtime (Control group)
Study: 17986032
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam 0.5 mg.kg (‐1)
Study: 17986032
Drug: Oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonidine 4 microg.kg (‐1)
Study: 9456288
Drug: celiprolol (200-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: celiprolol (200-400 mg daily)
Study: 2119168
Drug: sorbinil (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: sorbinil (250 mg daily for 3 years)
Study: 7435677
Drug: Amitriptyline alone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline alone, up to a maximum dose of 300 mg/day
Study: 7435677
Drug: Tranylcypromine alone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tranylcypromine alone, up to a maximum dose of 40 mg/day
Study: 7435677
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of amitriptyline (up to 150 mg/day) and tranylcypromine (up to 20 mg/day)
Study: 16877627
Drug: Randomised controlled
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomised controlled trial (RCT) for a new drug
Study: 7856175
Drug: Pravastatin 20
Normalized name: pravastatin 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 20 mg/day
Study: 10852357
Drug: 12-month treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-month treatment programs
Study: 10852357
Drug: Longer residential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longer residential treatment program
Study: 31897315
Drug: Lignocaine spray
Normalized name: lidocaine Mucosal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine spray (1 puff, 1.5 mg/kg)
Study: 31897315
Drug: Nitroglycerin spray
Normalized name: nitroglycerin Mucosal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin spray (1 puff, 400 μg)
Study: 11423812
Drug: Sequential presentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential presentation format
Study: 1722512
Drug: Parenteral gold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral gold therapy
Study: 30761786
Drug: Canephron N
Normalized name: N-6022
DrugBank: N-6022 (DB12206)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canephron N (2 tablets 3 times daily for 30 days)
Study: 30761786
Drug: Ciprofloxacin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (0.5 g twice daily for 3 days)
Study: 25382328
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose atorvastatin 80 mg followed by 20 mg/d (LD group)
Study: 23519529
Drug: Group 1:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1: 10 mg of lutein, 1 mg of zeaxanthin, 100 mg of docosahexaenoic acid, and 30 mg of eicosapentaenoic acid daily
Study: 23519529
Drug: Group 2:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2: Double the dose of Group 1
Study: 20943956
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg Zn/d as Zn sulfate
Study: 20943956
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg Zn/d as Zn sulfate
Study: 30383205
Drug: Intravitreal lampalizumab
Normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravitreal lampalizumab treatment
Study: 8941107
Drug: Metoprolol at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol at 125 to 150 mg/d
Study: 27267854
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate + prednisone (1,000 mg/d + 5 mg/d)
Study: 27267854
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate + exemestane (1,000 mg/d + 25 mg/d)